B-Vitamins Reduce Plasma Levels of beta amyloid
Authors
Leon Flicker, University of Western Australia
Ralph Martins, Edith Cowan University
Jenny Thomas, University of Western Australia
John Acres, University of Western Australia
Kevin Taddei, Edith Cowan UniversityFollow
Samuel Vasikaran, Royal Perth Hospital
Paul Norman, University of Western Australia
Konrad Jamrozik, University of Queensland
Osvaldo Almeida, University of Queensland
Document Type
Journal Article
Publisher
Elsevier
Faculty
Faculty of Computing, Health and Science
School
School of Exercise, Biomedical and Health Science / Centre of Excellence in Alzheimer’s Disease Research
RAS ID
6016
Abstract
Elevated plasma homocysteine (tHcy) is a risk factor for Alzheimer's disease (AD), and thus B vitamins may have a role in the prevention of AD. The objective of this study was to determine if tHcy lowering vitamins decrease the circulating levels of A-beta protein 1–40 (Aβ40). We randomized 299 older men to treatment with 2 mg of folate, plus 25 mg of B6 and 400 μg of B12, or placebo. After 2 years of treatment the mean (S.E.) increase of Aβ40 was 7.0 pg/ml (8.4) in the vitamin group (4.9%), and 26.8 pg/ml (7.7) (18.5%) in the placebo group. We conclude that B vitamins may decrease the plasma level of Aβ40 and have a role in the prevention of AD.
DOI
10.1016/j.neurobiolaging.2006.10.007
Comments
Flicker, L., Martins, R. N., Thomas, J., Acres, J., Taddei, K. , Vasikaran, S., Norman, P., Jamrozik, K., & Almeida, O. (2008). B-Vitamins reduce plasma levels of beta amyloid. Neurobiology of Aging, 29(2), 303-305. Available here